Amundi Has $1.21 Billion Position in Boston Scientific Corporation $BSX

Key Points

• Amundi has increased its stake in Boston Scientific Corporation by 2.6%, now holding approximately 12.3 million shares valued at $1.21 billion.
• Boston Scientific reported a 22.8% year-over-year revenue increase to $5.06 billion for the last quarter, surpassing analyst estimates.
• Multiple analysts have recently upgraded their price targets for Boston Scientific, with a consensus rating of "Buy" and an average target price of $117.50.

Amundi lifted its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 2.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 12,308,715 shares of the medical equipment provider's stock after purchasing an additional 311,034 shares during the quarter. Amundi owned about 0.83% of Boston Scientific worth $1,212,408,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of BSX. GAMMA Investing LLC grew its holdings in shares of Boston Scientific by 11,720.3% during the 1st quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider's stock worth $260,057,000 after purchasing an additional 2,556,078 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Boston Scientific by 18.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,839,362 shares of the medical equipment provider's stock worth $968,172,000 after purchasing an additional 1,709,461 shares during the period. Vanguard Group Inc. grew its holdings in shares of Boston Scientific by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock worth $13,577,311,000 after purchasing an additional 1,697,945 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Boston Scientific by 18.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider's stock worth $1,070,387,000 after purchasing an additional 1,664,108 shares during the period. Finally, Assenagon Asset Management S.A. grew its holdings in shares of Boston Scientific by 161.9% during the 1st quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider's stock worth $250,757,000 after purchasing an additional 1,536,663 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on BSX. Raymond James Financial increased their target price on Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 24th. Leerink Partnrs raised Boston Scientific to a "strong-buy" rating in a research report on Monday, June 16th. Citigroup reissued a "buy" rating and set a $125.00 target price (up previously from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Leerink Partners assumed coverage on Boston Scientific in a research report on Monday, June 16th. They set an "outperform" rating and a $118.00 target price on the stock. Finally, Barclays raised their price target on Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a research note on Thursday, July 24th. Three analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Boston Scientific has a consensus rating of "Buy" and a consensus price target of $117.79.

Insider Transactions at Boston Scientific

In related news, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the sale, the director owned 2,081 shares in the company, valued at $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the sale, the director owned 18,479 shares in the company, valued at $1,959,328.37. The trade was a 17.79% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 174,214 shares of company stock valued at $18,397,457. Company insiders own 0.50% of the company's stock.

Boston Scientific Trading Up 0.7%

Shares of NYSE:BSX traded up $0.80 during midday trading on Monday, reaching $108.02. The company's stock had a trading volume of 3,545,947 shares, compared to its average volume of 7,441,182. The business has a 50 day moving average price of $104.77 and a 200 day moving average price of $102.15. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $108.94. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The firm has a market cap of $160.05 billion, a price-to-earnings ratio of 64.33, a price-to-earnings-growth ratio of 2.58 and a beta of 0.65.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the previous year, the business earned $0.62 earnings per share. The firm's quarterly revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.